Viatris falls after resolving opioid-related claims for $335 mln
Shares of the drug maker Viatris VTRS.O fall about 3.6% to $7.34, its lowest since 2008
Co says it would pay up to $335 mln over nine years as part of a nationwide settlement to resolve opioid-related claims
VTRS to pay between $27.5 mln and $40 mln annually toward state and local opioid initiatives
Including session moves, stock down about 42% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SpaceX IPO Guide: Can You Buy SpaceX IPO Shares on Robinhood? How Can Investors in Asia and Europe Buy SpaceX IPO Shares?

Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

Chevron Stock Analysis: A Stock Warren Buffett Bet Big On—Should You Invest in 2026 Despite High Oil Prices?

IonQ vs. Rigetti Computing: Which Quantum Computing Stock Has the Edge Now?

Tradingkey








